Getinge AB
STO:GETI B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (9.2), the stock would be worth kr206.12 (6% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.7 | kr194 |
0%
|
| 3-Year Average | 9.2 | kr206.12 |
+6%
|
| 5-Year Average | 9.6 | kr214.95 |
+11%
|
| Industry Average | 9.2 | kr205.83 |
+6%
|
| Country Average | 14.9 | kr332.14 |
+71%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
kr57.6B
|
/ |
Jan 2026
kr6.7B
|
= |
|
|
kr57.6B
|
/ |
Dec 2026
kr6.9B
|
= |
|
|
kr57.6B
|
/ |
Dec 2027
kr7.5B
|
= |
|
|
kr57.6B
|
/ |
Dec 2028
kr8.1B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
Getinge AB
STO:GETI B
|
52.8B SEK | 8.7 | 23.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170B USD | 45.1 | 59.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
160.6B USD | 14 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.1B USD | 19.9 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.5B USD | 12.9 | 23.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
97.4B USD | 19.9 | 33.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.6B EUR | 10.8 | 19.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 23.4 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 29.9 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.1B USD | 10 | 25.1 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.9B USD | 11.1 | 15.3 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.4 |
| Median | 14.9 |
| 70th Percentile | 19.4 |
| Max | 4 325.3 |
Other Multiples
Getinge AB
Glance View
Getinge AB, rooted in the lush landscapes of Sweden, has steadily evolved into a global leader in the medical technology sector. The company began its journey by manufacturing traditional sterilizers over a century ago. Over time, Getinge has carefully navigated and adapted to the ever-changing dynamics of the healthcare industry, positioning itself squarely at the intersection of innovation and practicality. Today, Getinge specializes in a broad spectrum of medical equipment and systems, focusing on critical care, surgery, and infection prevention. This focus is intricately designed to cater to hospitals and healthcare facilities worldwide, ensuring that patients receive the highest standard of care during complex procedures and critical conditions. Revenue streams for Getinge are as diversified as its product portfolio, comprising equipment sales, service contracts, and consumables. The company’s product offerings range from sophisticated ventilators and state-of-the-art heart-lung machines, to efficient sterilization and surgical workflow products. Beyond simply selling devices, Getinge builds sustainable revenue through long-term service agreements and the sale of replacement parts and consumables, which are essential for the ongoing, optimal operation of its technologically advanced machinery. This strategic emphasis on combining cutting-edge product development with a robust support infrastructure underscores Getinge’s business model, ensuring loyalty and ongoing relationships with healthcare institutions globally.